Jiang T, Li Y, Zhang N, Gan L, Su H, Xiang G
Ther Adv Drug Saf. 2025; 16():20420986241308089.
PMID: 39802043
PMC: 11724423.
DOI: 10.1177/20420986241308089.
Seervai R, Paz Munoz E, Freeman S, Swords R, White K, Keller J
JAAD Case Rep. 2024; 54:89-92.
PMID: 39687070
PMC: 11646748.
DOI: 10.1016/j.jdcr.2024.09.013.
Cowen E, Barrios D, Pulitzer M, Moy A, Dusza S, De Wolf S
Acta Haematol. 2023; 147(4):457-464.
PMID: 37989105
PMC: 11740260.
DOI: 10.1159/000535399.
Milnerowicz S, Maszewska J, Skowera P, Stelmach M, Lejman M
Int J Mol Sci. 2023; 24(21).
PMID: 37958832
PMC: 10647248.
DOI: 10.3390/ijms242115849.
Zhou Y, Yin Y, Huang X, Hu Y, He Q
Zhejiang Da Xue Xue Bao Yi Xue Ban. 2023; 52(5):544-557.
PMID: 37899395
PMC: 10630053.
DOI: 10.3724/zdxbyxb-2023-0261.
Differentiation Syndrome in Acute Leukemia: APL and Beyond.
Woods A, Norsworthy K
Cancers (Basel). 2023; 15(19).
PMID: 37835461
PMC: 10571864.
DOI: 10.3390/cancers15194767.
From the Deep: Overlap of Neutrophilic Dermatoses Disorders Associated With Acute Myeloid Leukemia.
Martins M, Barbosa J, Eusebio S, Prayce R, Pires P
Cureus. 2023; 15(1):e33456.
PMID: 36751214
PMC: 9897686.
DOI: 10.7759/cureus.33456.
The FLT3 Y842D mutation may be highly sensitive to midostaurin: a case report.
He S, Zhang M, Li J, Zhao W, Yu L, Han Y
J Int Med Res. 2022; 50(5):3000605221097774.
PMID: 35549749
PMC: 9251825.
DOI: 10.1177/03000605221097774.
Neutrophilic Dermatoses: a Clinical Update.
Weiss E, Ko C, Leung T, Micheletti R, Mostaghimi A, Ramachandran S
Curr Dermatol Rep. 2022; 11(2):89-102.
PMID: 35310367
PMC: 8924564.
DOI: 10.1007/s13671-022-00355-8.
FDA Approval Summary: Gilteritinib for Relapsed or Refractory Acute Myeloid Leukemia with a Mutation.
Pulte E, Norsworthy K, Wang Y, Xu Q, Qosa H, Gudi R
Clin Cancer Res. 2021; 27(13):3515-3521.
PMID: 33632926
PMC: 8506653.
DOI: 10.1158/1078-0432.CCR-20-4271.
Differentiation therapy of myeloid leukemia: four decades of development.
Madan V, Koeffler H
Haematologica. 2020; 106(1):26-38.
PMID: 33054125
PMC: 7776344.
DOI: 10.3324/haematol.2020.262121.
Sweet's syndrome in a granulocytopenic patient with acute myeloid leukemia on FLT3 inhibitor.
Paudel A, Dhital R, Areoye G, Basnet S, Tachamo N
J Community Hosp Intern Med Perspect. 2020; 10(3):275-278.
PMID: 32850078
PMC: 7426991.
DOI: 10.1080/20009666.2020.1766818.
Differentiation Syndrome with Ivosidenib and Enasidenib Treatment in Patients with Relapsed or Refractory IDH-Mutated AML: A U.S. Food and Drug Administration Systematic Analysis.
Norsworthy K, Mulkey F, Scott E, Ward A, Przepiorka D, Charlab R
Clin Cancer Res. 2020; 26(16):4280-4288.
PMID: 32393603
PMC: 7442588.
DOI: 10.1158/1078-0432.CCR-20-0834.
Recent drug approvals for acute myeloid leukemia.
Lai C, Doucette K, Norsworthy K
J Hematol Oncol. 2019; 12(1):100.
PMID: 31533852
PMC: 6749668.
DOI: 10.1186/s13045-019-0774-x.
Gilteritinib induces differentiation in relapsed and refractory -mutated acute myeloid leukemia.
McMahon C, Canaani J, Rea B, Sargent R, Qualtieri J, Watt C
Blood Adv. 2019; 3(10):1581-1585.
PMID: 31122910
PMC: 6538870.
DOI: 10.1182/bloodadvances.2018029496.
Insights Into the Pathogenesis of Sweet's Syndrome.
Heath M, Ortega-Loayza A
Front Immunol. 2019; 10:414.
PMID: 30930894
PMC: 6424218.
DOI: 10.3389/fimmu.2019.00414.
The role of targeted therapy in the management of patients with AML.
Perl A
Blood Adv. 2018; 1(24):2281-2294.
PMID: 29296877
PMC: 5737125.
DOI: 10.1182/bloodadvances.2017009829.
The role of targeted therapy in the management of patients with AML.
Perl A
Hematology Am Soc Hematol Educ Program. 2017; 2017(1):54-65.
PMID: 29222237
PMC: 6142552.
DOI: 10.1182/asheducation-2017.1.54.
The Future of Targeting FLT3 Activation in AML.
Leick M, Levis M
Curr Hematol Malig Rep. 2017; 12(3):153-167.
PMID: 28421420
DOI: 10.1007/s11899-017-0381-2.
Evidence for Clinical Differentiation and Differentiation Syndrome in Patients With Acute Myeloid Leukemia and IDH1 Mutations Treated With the Targeted Mutant IDH1 Inhibitor, AG-120.
Birendra K, DiNardo C
Clin Lymphoma Myeloma Leuk. 2016; 16(8):460-5.
PMID: 27245312
PMC: 4983480.
DOI: 10.1016/j.clml.2016.04.006.